Citadel Advisors
CTNM

Citadel Advisors’s Contineum Therapeutics CTNM Stock Holding History

Citadel Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.5M Buy
396,354
+46,154
+13% +$605K ﹤0.01% 4266
2026
Q1 		$4.57M Buy
+350,200
New +$4.7M ﹤0.01% 4492
2025
Q3 		– Sell
-16,489
Closed -$65.5K – 14370
2025
Q2 		$65.5K Buy
+16,489
New +$71.7K ﹤0.01% 11629
2024
Q3 		– Sell
-127,785
Closed -$2.25M – 15434
2024
Q2 		$2.25M Buy
+127,785
New +$2.06M ﹤0.01% 5096

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's CTNM Position: Q2 2026 in Review

Citadel Advisors increased its Contineum Therapeutics (CTNM) stake by 13% in Q2 2026, buying an estimated $605K and bringing the position to 396,354 shares worth $6.5M. The position accounts for ﹤0.01% of the portfolio, ranked #4266.

Citadel Advisors first reported a position in CTNM in Q2 2024 and has held it in 4 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Citadel Advisors held 396,354 shares of Contineum Therapeutics worth $6.5M as of Q2 2026.
  • Citadel Advisors bought 46,154 Contineum Therapeutics shares in Q2 2026, an estimated $605K.
  • Contineum Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4266 holding.
  • Citadel Advisors first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.